REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX

REGENXBIO Inc. (NASDAQ: RGNX) is facing a class-action lawsuit for alleged securities law violations, initiated by law firm Levi & Korsinsky, LLP. The lawsuit seeks to represent investors who suffered losses due to alleged securities fraud that occurred from February 9, 2022, to January 27, 2026. Central to the complaint are claims that REGENXBIO misled investors regarding the development and commercial prospects of its gene therapy product candidate, RGX-111, designed to treat severe Mucopolysaccharidosis Type I, or Hurler syndrome.

The lawsuit alleges that REGENXBIO made overly optimistic statements about RGX-111's trial outcomes based on positive data from ongoing studies while failing to disclose critical safety and efficacy concerns. A significant turning point came on January 28, 2026, when the company announced that the FDA had imposed a clinical hold on RGX-111 after a participant in the Phase I/II study developed an intraventricular CNS tumor. This news triggered a dramatic decline in REGENXBIO’s stock price, plummeting 17.8% in just one day, from $13.41 to $11.01 per share.

Investors affected by these events have until April 14, 2026, to claim their rights to compensation and potentially be appointed as lead plaintiffs in the case. Participation in the lawsuit is at no cost to investors. Levi & Korsinsky, with over 20 years of experience and a strong track record in securities litigation, encourages impacted investors to reach out for more information. They can do so via email at jlevi@levikorsinsky.com or by calling (212) 363-7500.

**Market Analysis and Advice on REGENXBIO Inc. (RGNX)**

REGENXBIO Inc. (NASDAQ: RGNX) is currently facing a class action lawsuit alleging securities law violations. The suit arises from claims that the company misled investors about its key product candidate, RGX-111, a gene therapy intended for treating Hurler syndrome. Recent developments, particularly the FDA placing a clinical hold on RGX-111 after a serious adverse event (an intracranial tumor) was reported, have sharply impacted the stock price, driving it down nearly 18% in just one day.

For current and potential investors, it's crucial to approach RGNX with caution. The implications of the lawsuit may not only affect the company's market reputation but also its operational trajectory. Legal proceedings can extend over months or even years, creating uncertainty in the stock's performance during this time. Therefore, investors should closely monitor the developments concerning the lawsuit and any updates on RGX-111's clinical status.

Investors impacted by the stock’s decline during the alleged fraudulent period should consider reaching out to legal counsel, such as Levi & Korsinsky, to explore potential recovery options. The firm has a history of successful litigation in securities claims and could provide insights into the viability of individual claims within the context of the class action.

For those contemplating holding RGNX shares, it may be prudent to reassess the portfolio’s exposure to biotech stocks given the current regulatory scrutiny and market volatility. Lastly, with RGNX's share price at $11.01, investors should evaluate if the stock’s current value reflects its potential recovery prospects or if the legal risks outweigh possible gains. In summary, exercise due diligence and prepare for extended volatility as the situation evolves.